Dr Carbone talks with ecancer at the Best of ASCO 2017 meeting in Miami about the developments of targeted therapies for EGFR and ALK mutations in advanced lung cancer patients. He goes on to discuss the new drugs that have been yielding improved efficacy...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uIh30w
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Geriatric trauma: A population-based study Saint Shiou-Sheng Chen, Li-Chien Chien Formosan Journal of Surgery 2019 52(2):39-44 Background: G...
-
Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved ...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Related Articles Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients wit...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Related Articles Disrupted relationship between "resting state" connectivity and task-evoked activity during social percepti...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου